« Run! Anthropologists! |
| The Choir Hears It Again »
August 3, 2007
Not Necessarily So
My travel schedule has left me little time for blogging this morning, so I wanted just to report that I'll be revisiting some of the recent topics around here. My post on virtual companies led to a number of examples being sent to me - I want to look them over and report back. It's my guess that many of these deal with generic drugs or abandoned products, but we'll see. I still don't see how this model would work on a large scale (Pfizer, anyone?), but perhaps there's room for it on a smaller one.
And my post on abandoning the likes of tin, HMPA, and other nasties in med-chem research bought in quite a few counterexamples. I put a note up on that entry to direct new readers of it to the comments, so as not to miss them. I think that different companies treat these issues differently - in some shops, the med chem labs are encouraged to do whatever it takes to make the compounds, with the expectations that process chemistry will straighten out the kinks. Other companies, though, frown on that as irresponsibly throwing the problem over the wall to the next group, and want their med-chem people to forestall such problems if they can. I'll do a whole post on that subject next week, if possible, and we'll take an informal head count.
These bring up a general thought: as with any blog, this one is a reflection of my own experience and biases. (That's the whole point of a blog, eh?) I like the fact, though, that there are so many readers around the industry to confirm or disprove things as they come up. It's my hope that the non-industry audience finds the back and forth on these topics worth reading - I have a mixed crowd around here, and I try to keep things readable for anyone interested who happens by.
+ TrackBacks (0) | Category: Blog Housekeeping
POST A COMMENT
- RELATED ENTRIES
- Shire's Replagal Problems: An Inside Look?
- Bungled Structure, And How
- Roche Closes Nutley, Once Its US R&D Home
- The Next Five Years in the Drug Industry
- A Kinase Inhibitor Learns Something New
- The Good Ol' Friedel-Crafts
- Merck's Madagascar Marketing Mess
- Scientific Literacy: Where Do You Stop?